Archives
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
A large body of literature
2022-06-14

A large body of literature have reported that various cellular pathways are dysregulated in NPC [19]. Among these pathways, Akt is frequently hyperactivated in NPC and regulates diverse cellular processes including tumor cell growth, proliferation, metabolism, survival and invasion, as well as angio
-
In studies described earlier IRL was administered intravenou
2022-06-14

In studies described earlier, IRL-1620 was administered intravenously; however, because of its short half-life (Rubin and Levin, 1994) (about 7–8min), the dosing had to be repeated three times. Also, a dose-dependent hypotension was observed with repeated doses of IRL-1620 in rats (Leonard and Gulat
-
The presence of the H receptor in humans was
2022-06-13

The presence of the H3 receptor in humans was confirmed approximately 25 years ago, and the receptor was successfully cloned in 1999 (Thurmond, 2010). The H3 receptor is unique, as it controls feedback of histamine release, particularly in the central nervous system, where it modulates neurotransmit
-
EdU is a thymidine analog that is incorporated
2022-06-13

EdU is a thymidine analog that is incorporated into replicated chromosomal DNA during the S phase of the cell cycle. DAPI is a fluorescent dye that binds strongly to A-T-rich regions in DNA and is commonly used for cell nucleus staining. We used the EdU incorporation assay, which is a highly sensiti
-
In HO OE group Barnesiella Eubacterium Parvibacter
2022-06-13

In HO-1OE group, Barnesiella, Eubacterium, Parvibacter and were notably enriched in the gut. Barnesiella, belonging to Porphyromonadaceae, is able to utilize fucosyllactose as gap-26 source to maintain bacterial cultures (Weiss et al., 2014). The enrichment of this microbial genus was consistent wit
-
The synthesis of target compound RS
2022-06-13

The synthesis of target compound (RS)-C02 is illustrated as Scheme 2. Compound (RS)-3 was synthesized as reported procedures [40] and then reacted with ethyl piperidine-4-carboxylate to yield (RS)-C01, which subsequently was converted to target molecule (RS)-C02 by performing a nucleophilic substitu
-
Our data demonstrate that cobas HCV s performance characteri
2022-06-13

Our data demonstrate that cobas HCV’s performance characteristics meet these requirements, making the assay useful in the management of therapy for chronic hepatitis C. We documented that cobas HCV has the requisite LOD, measureable range (15 − 1.0E + 08 IU/mL) and precision allowing for baseline HC
-
br Conclusion Interactions between neurons and
2022-06-13

Conclusion Interactions between neurons and astrocytes depend on the spatial configuration of their contacts. Therefore, changes of astrocyte morphology may impact various physiological mechanisms ranging from glutamate uptake and potassium homeostasis to modulation of synaptic transmission and p
-
It has been shown that GPR receptors coupled
2022-06-13

It has been shown that GPR55 receptors coupled to G12/13 proteins down-regulate reactive oxygen species (ROS) production and degranulation in human neutrophils [9]. MCs degranulation stimulated by IgE/Ag also requires the generation of ROS [64]; therefore, the possibility to explore the inhibitory a
-
br Conflict of interest br Acknowledgment
2022-06-13

Conflict of interest Acknowledgment This work was supported by National Program on Key Basic Research Project of China (No. 2013CB127305); The National Natural Science Foundation of China (No. 314020785); Hubei Provincial Creative Team Project of Agricultural Science and Technology (No. 2007-6
-
br Author s contributions br Conflict of interest
2022-06-13

Author's contributions Conflict of interest Acknowledgements This work was supported in part by a grant from Department of Biotechnology (DBT), Government of India (Sanction Order No.: BT/563/NE/U-Excel/2016). MC, PDG and SKM acknowledge the Ministry of Human Resource and Development (MHRD)
-
To confirm that these were bona fide interactions we investi
2022-06-13

To confirm that these were bona fide interactions, we investigated whether the potassium channel subunits or Tmem263 formed complexes with GLT-1 or DAT after immunoprecipitation. Lysates of HEK-293 cells previously cotransfected with HA-GLT-1 or HA-DAT, and either YFP-Kv7.3, YFP-Kv7.2 or YFP-Kv7.5 w
-
Peripheral injury or disease induced alterations in synaptic
2022-06-13

Peripheral injury- or disease-induced alterations in synaptic efficacy occur not only at the first synapse made by the primary nociceptive afferents in the spinal dorsal horn but are also operational in several regions processing the sensorimotor as well as emotional-affective components of pain, su
-
CSL is endowed with an intrinsic transcription repressive fu
2022-06-13

CSL is endowed with an intrinsic transcription-repressive function, and CAF-effector genes are induced as a consequence of CSL downmodulation (Hu et al., 2012, Procopio et al., 2015), as it can occur upon exposure to pro-carcinogenic stimuli such as UVA or smoke-derived compounds (Menietti et al., 2
-
The extensive worldwide research efforts in the decade follo
2022-06-10

The extensive worldwide research efforts in the decade following FFA1 de-orphaning aimed at developing clinically useful FFA1 agonists were nearly halted after Takeda’s first-in-class agent fasiglifam (TAK-875) was discontinued in phase III of human trials. On the date of submission of this manuscr
15935 records 410/1063 page Previous Next First page 上5页 406407408409410 下5页 Last page